Cargando…

A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration—the FALCON study

BACKGROUND: Treatment initiation with brolucizumab, a new potent anti-vascular endothelial growth factor (VEGF) agent, is typically performed with three monthly injections (loading dose) and has been well studied in treatment-naïve patients. However, no clinical data are available yet on whether or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holz, F. G., Schmitz-Valckenberg, Steffen, Wolf, A., Agostini, H., Lorenz, K., Pielen, A., Feltgen, N., Guthoff, R., Quiering, C., Clemens, A., Jaeger, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Medical Ophthalmology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325853/ https://www.ncbi.nlm.nih.gov/pubmed/35188581 http://dx.doi.org/10.1007/s00417-022-05591-z

Ejemplares similares

Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation
por: Carta, Valentina, et al.
Publicado: (2023)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration
por: Weber, Constance, et al.
Publicado: (2022)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization
por: Gao, Rui, et al.
Publicado: (2021)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment
por: Holz, Frank G., et al.
Publicado: (2022)

Ocular Coloboma With Choroidal Neovascular Membrane: A Case Report
por: Almasaud, Jluwi, et al.
Publicado: (2021)

Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study
por: Thinggaard, Benjamin Sommer, et al.
Publicado: (2023)

Intermediate Uveitis Complicated by Peripapillary Choroidal Neovascularization
por: Nageeb, Mohammed R
Publicado: (2022)

Deep Learning Classification of Drusen, Choroidal Neovascularization, and Diabetic Macular Edema in Optical Coherence Tomography (OCT) Images
por: Riazi Esfahani, Parsa, et al.
Publicado: (2023)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Ocular Sarcoidosis Limited to Retinal Vascular Ischemia and Neovascularization
por: Dyer, Gawain, et al.
Publicado: (2016)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study
por: Thier, Anne, et al.
Publicado: (2022)

Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland
por: Korva-Gurung, Ida, et al.
Publicado: (2023)

Neovascular Glaucoma Progress and Impact of Therapeutic Intervention in Saudi Arabia
por: AlRubaie, Khalid, et al.
Publicado: (2021)

Bilateral Neovascular Glaucoma With Retinitis Pigmentosa: A Clinical Challenge
por: Cruz, Rakhi D, et al.
Publicado: (2022)

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
por: Arrigo, Alessandro, et al.
Publicado: (2022)

Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study
por: Sim, Peng Yong, et al.
Publicado: (2017)

Response of Pediatric Choroidal Neovascularization to Anti-Vascular Endothelial Growth Factor
por: Ruparelia, Sunil, et al.
Publicado: (2021)

Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials
por: Zhao, Xinyu, et al.
Publicado: (2021)

Re: Trivizki et al. Local Geographic Atrophy Growth Rates Not Influenced by Close Proximity to Non-Exudative Type 1 Macular Neovascularization
por: Pfau, Maximilian, et al.
Publicado: (2022)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution
por: Skrzypczak, Tomasz, et al.
Publicado: (2021)

Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
por: Reeves, Barnaby C, et al.
Publicado: (2016)

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
por: Zuccarini, Silvio, et al.
Publicado: (2022)

Choroidal Neovascularization and Toxic Optic Neuropathy Secondary to Tobacco Use: A Case Report
por: Islam, Yasmin, et al.
Publicado: (2020)

Optic Disc Neovascularization as the Only Sign of Ocular Ischemic Syndrome: A Case Report
por: Metry, Youstina, et al.
Publicado: (2022)

Adjuvant Intravitreal Bevacizumab for Retinal Neovascularization in Eales’ Disease Associated With Latent Mycobacterium Tuberculosis
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

FENETRE study: quality-assured follow-up of quiescent neovascular age-related macular degeneration by non-medical practitioners: study protocol and statistical analysis plan for a randomised controlled trial
por: Learoyd, Annastazia E, et al.
Publicado: (2021)

Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model
por: Thomas, Darren S, et al.
Publicado: (2022)

Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) for neovascular age-related macular degeneration: a cross-sectional diagnostic accuracy study
por: von der Burchard, Claus, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s9vr31laqv3ci4ju06jpe47rgu